Tegral tablets, containing carbamazepine, may impact individuals with liver disease. Carbamazepine is linked to liver toxicity, often requiring regular liver function tests during treatment to monitor liver health.
For patients with liver disease, close supervision is necessary, and the decision to use Tegral tablets should be made after a comprehensive evaluation of the risks and benefits by a healthcare provider.
